News
![Western Union to Present at the Wolfe FinTech Forum: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24835/375px-Western_Union_money_transfer.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBc2tDIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--0816ae8af05ddeb070c715750e96df42009b12d4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/375px-Western_Union_money_transfer.png?locale=us)
Western Union to Present at the Wolfe FinTech Forum
The Western Union Company (NYSE: WU), a global leader in cross-border, cross-currency money movement and payments, today announced that the Company will present at the Wolfe FinTech Forum on
![Form 8.3 - The Vanguard Group, Inc.: NortonLife Lock Inc.http://www.icatcher.com/wp-content/uploads/2012/04/Symantec.jpg: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/12176/Symantec.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdEVCIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--1b3c47f309e54c35ff476143bba270ac36f5bc61/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Symantec.jpg?locale=us)
Form 8.3 - The Vanguard Group, Inc.: NortonLife Lock Inc.
![Biomind Labs Announces DTC Eligibility in the United States: https://mms.businesswire.com/media/20220217005440/en/1363327/5/Biomind_Logo_2022.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMmo5Vnc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2fe10e2011f4b07703d1ff35d359d71f545d7686/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Biomind_Logo_2022.jpg?locale=us)
Biomind Labs Announces DTC Eligibility in the United States
Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: CRSWF) (FSE: 3XI), a leading biotech company focused on innovation and research on endogenous tryptamines (biomolecules acting
![SunOpta Announces Fourth Quarter and Fiscal 2021 Financial Results: https://mms.businesswire.com/media/20191106005259/en/565486/5/SunOptaIncTagLogo_3COL_BLK.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBenNpRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--140835c366dcf8b87698bc25e26787109c34708c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/SunOptaIncTagLogo_3COL_BLK.jpg?locale=us)
SunOpta Announces Fourth Quarter and Fiscal 2021 Financial Results
SunOpta Inc. (“SunOpta” or the “Company”) (Nasdaq:STKL) (TSX:SOY), a leading healthy food and beverage company focused on plant-based foods and beverages and fruit-based foods and beverages, today
![Xebec Announces Board Resignation of Karen Nielsen: https://mms.businesswire.com/media/20220201005360/en/1344855/5/xebec-box-logo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMFBsVnc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0cbe24680e71528ac576b7b63d0c5a6c81f405fe/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/xebec-box-logo.jpg?locale=us)
Xebec Announces Board Resignation of Karen Nielsen
Xebec Adsorption Inc. (TSX: XBC) (“Xebec”), a global provider of sustainable gas technologies, announced today that Karen Nielsen, has resigned as a member of Xebec’s Board of Directors as of
![New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor Response: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLzJBRWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5cbb888b15fc1babe89717dad3b9d241825019eb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/novocure_main-405x.jpg?locale=us)
New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor Response
Novocure (NASDAQ: NVCR) today announced that a new study published in the Journal of Clinical Investigation (JCI) finds treatment with Tumor Treating Fields (TTFields) mediated cell disruption
![Lawson Products Reports Fourth Quarter and Full Year 2021 Results: https://mms.businesswire.com/media/20200206005031/en/191765/5/LP_Logo_2007_yellowbox.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeS9USVE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8ada3e98f003ffd9b6414922b6afa266394e8874/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/LP_Logo_2007_yellowbox.jpg?locale=us)
Lawson Products Reports Fourth Quarter and Full Year 2021 Results
Lawson Products, Inc. (NASDAQ:LAWS) ("Lawson" or the "Company"), a distributor of products and services to the MRO marketplace, today announced results for the fourth quarter and the full year
![Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLzJBRWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5cbb888b15fc1babe89717dad3b9d241825019eb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/novocure_main-405x.jpg?locale=us)
Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
Novocure (NASDAQ: NVCR) today reported financial results for the fourth quarter and full year ended December 31, 2021. Novocure is a global oncology company working to extend survival in some of
Newmont Delivers Strong Full-Year and Fourth Quarter 2021 Results
Newmont Corporation (NYSE: NEM, TSX: NGT) (Newmont or the Company) today announced full year and fourth quarter 2021 results.
2021 HIGHLIGHTS
-
Produced 6.0 million attributable ounces of gold
DGAP-Adhoc: alstria office REIT-AG: Dividend proposal for financial year 2021
![NICE Recognized as a Top Provider for Conversational AI Applications and Chatbots by Metrigy: https://mms.businesswire.com/media/20191203005409/en/615391/5/NICE_inContact.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBemtvRlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--06f22a0c3a8fabdec4f231cf3ebdea0279feec53/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/NICE_inContact.jpg?locale=us)
NICE Recognized as a Top Provider for Conversational AI Applications and Chatbots by Metrigy
NICE (Nasdaq: NICE) today announced that it has been recognized as a MetriStar Top Provider in the Conversational AI Applications category, out of a total of 23 companies evaluated. The ranking was
![Valbiotis Presents Its 2022 Financial Communication Calendar: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNXFzSVE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--15bfdf03f8ab493929a3d2392e314697d3469f59/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/valbiotis-logo.jpg?locale=us)
Valbiotis Presents Its 2022 Financial Communication Calendar
Regulatory News:
Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA/SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic
Nordea Bank Abp: Transaction in Own Shares
![Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPSIIIA](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPSIIIA
Regulatory News:
Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today provides an update on clinical results and timelines
![SES Full Year 2021 Results: https://mms.businesswire.com/media/20191129005253/en/290384/5/SES_Logo_BL_M.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeHRZRkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--47420c82142be2d536d2fc244215ced782ecd26b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/SES_Logo_BL_M.jpg?locale=us)
SES Full Year 2021 Results
SES S.A. announces financial results for the year ended 31 December 2021.
Solid performance delivering revenue of €1,782 million and Adjusted EBITDA(1) of €1,091 million at top end of financial
DGAP-News: Lloyds Banking Group PLC: 2021 Full Year Results
DGAP-News: Lloyds Banking Group PLC: 2021 Annual Report and Accounts
DGAP-News: AIXTRON: Continued growth in all dimensions / 65% more orders and 59% higher revenues in 2021 / Record shipments in Q4/21 / Double-digit growth for 2022 / High EU taxonomy aligned figures
DGAP-News: Krones AG: Krones significantly increases revenue, order intake and profitability in 2021
DGAP-News: TAKKT AG: TAKKT with strongest organic growth in company's history
DGAP-News: Aareal Bank posts marked increase in profits for the financial year 2021, setting itself new growth targets
![Nutrien Announces Ken Seitz as a Speaker at the BMO and BofA Investor Conferences: https://mms.businesswire.com/media/20191104006030/en/699432/5/Nutrien_logo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNnNpRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e3497280ba634d92aadbfc5a122d051780b36337/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Nutrien_logo.jpg?locale=us)
Nutrien Announces Ken Seitz as a Speaker at the BMO and BofA Investor Conferences
Nutrien Ltd. (TSX and NYSE: NTR) announced today that Mr. Ken Seitz, Nutrien’s Interim President and Chief Executive Officer, will be speaking at the BMO Global Metals and Mining Conference on
![CI Financial Reports Total Assets of $372.5 Billion for January 2022: https://mms.businesswire.com/media/20201105006022/en/836403/5/CI-F_-_RGB_E.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBem1LVlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3d8fb424903fcea7ece1d64c4b0c3bb9003ef63e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/CI-F_-_RGB_E.jpg?locale=us)
CI Financial Reports Total Assets of $372.5 Billion for January 2022
CI Financial Corp. (“CI”) (TSX: CIX, NYSE: CIXX) today reported preliminary assets under management as at January 31, 2022 of $146.4 billion and wealth management assets of $226.1 billion, for
![Orbia Announces Fourth Quarter and Full Year 2021 Financial Results: https://mms.businesswire.com/media/20200429005967/en/788507/5/Orbia_PrimaryLogo_Blue.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeU4xTWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b2318c1aeacf7e4b1388608ee3afa0318d3581cf/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Orbia_PrimaryLogo_Blue.jpg?locale=us)
Orbia Announces Fourth Quarter and Full Year 2021 Financial Results
Orbia Advance Corporation, S.A.B. de C.V. (BMV: ORBIA*) (“the Company” or “Orbia”) today released audited results for the fourth quarter and full year of 2021.
Orbia achieved solid performance
![RRD Announces Expiration of Its Consent Solicitation for Its 2029 Debentures](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
RRD Announces Expiration of Its Consent Solicitation for Its 2029 Debentures
R.R. Donnelley & Sons Company (NYSE: RRD) (“RRD” or the “Company”) today announced the expiration of its previously announced solicitation of consents (the “Consent Solicitation”) from holders of